Analyst Ratings For Heron Therapeutics (NASDAQ:HRTX)
Today, Needham & Company LLC raised its price target on Heron Therapeutics (NASDAQ:HRTX) to per share.
Some recent analyst ratings include
- 3/19/2018-Cowen Reiterated Rating of Buy.
- 3/19/2018-Mizuho Reiterated Rating of Buy .
- 3/2/2018-Noble Financial Reiterated Rating of Buy.
- On 3/19/2018 Barry D Quart, CEO, sold 100,000 with an average share price of $29.75 per share and the total transaction amounting to $2,975,000.00.
- On 3/19/2018 Kimberly Manhard, VP, sold 18,000 with an average share price of $30.00 per share and the total transaction amounting to $540,000.00.
- On 3/14/2018 Barry D Quart, CEO, sold 100,000 with an average share price of $24.75 per share and the total transaction amounting to $2,475,000.00.
- On 1/10/2018 Kimberly Manhard, VP, sold 7,584 with an average share price of $20.00 per share and the total transaction amounting to $151,680.00.
- On 4/24/2017 Kimberly Manhard, VP, sold 21,542 with an average share price of $15.33 per share and the total transaction amounting to $330,238.86.
- On 1/19/2017 Kevin C Tang, Director, bought 2,459,016 with an average share price of $12.20 per share and the total transaction amounting to $29,999,995.20.
- On 8/10/2016 Robert Rosen, Insider, sold 100,000 with an average share price of $23.30 per share and the total transaction amounting to $2,330,000.00.
Recent Trading Activity for Heron Therapeutics (NASDAQ:HRTX)
Shares of Heron Therapeutics closed the previous trading session at 27.25 down -0.05 0.18% with shares trading hands.